Allergy during breastfeeding
Allergic rhinitis, urticaria, and other allergic conditions in a breastfeeding woman. Per LactMed and ARIA 2023, drugs of choice: loratadine (RID 0.04%, Hale L1), cetirizine (RID 1.5%, Hale L2), bilastine, fexofenadine. Avoid sedating 1st-generation agents (high-dose diphenhydramine, promethazine) due to theoretical milk-supply reduction and infant drowsiness.
ICD-10 T78.44 drugs
Also known as: Hay fever while breastfeeding
Marketing claims without evidence base
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
- CChlorpheniramineNot recommended · First-generation moderately sedating antihistamineChlorpheniramine while breastfeeding. RID about 0.9%, Hale L3. Compatible as a single low dose. Long-term use may reduce milk supply and cause infant drowsiness. Avoid combination cold products with pseudoephedrine – a single 60 mg dose reduces milk supply by 24%.
- CDiphenhydramineNot recommended · First-generation sedating antihistamineDiphenhydramine while breastfeeding. RID about 1%, Hale L2. A single low dose is safe. Repeated high doses may theoretically reduce milk supply (anticholinergic) and cause infant drowsiness. Prefer loratadine (Hale L1) or cetirizine.
- DKetotifenNot recommended · Antihistamine + mast cell stabilizerKetotifen while breastfeeding – limited data. Hale L3. Sedating, theoretical infant drowsiness risk. Prefer loratadine and cetirizine with better safety profile and faster onset.
- DPromethazineNot recommended · First-generation phenothiazine antihistamine, strongly sedatingPromethazine while breastfeeding is undesirable. RID not precisely estimated, Hale L3 due to limited data. Infant risks marked sedation, apnea, paradoxical excitation. Due to FDA black box on fatal respiratory depression in children <2, nursing mothers should avoid regular use. If prescribed long-term, consider a second opinion.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit